{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:11:43Z","timestamp":1792552303496,"version":"4.5.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Bruton tyrosine kinase (BTK) is a validated target for treatment of B-cell malignancies, and oral inhibitors of BTK have emerged as a standard of care for these diseases. Acalabrutinib is a second generation, highly selective, potent, covalent BTK inhibitor that exhibits minimal off-target activity in\n                    <jats:italic>in vitro<\/jats:italic>\n                    assays, providing the potential to improve tolerability over the first-in-class BTK inhibitor, ibrutinib. Acalabrutinib was approved for the treatment of relapsed\/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) in the US in 2017 and 2019, respectively. Acalabrutinib is also undergoing trials for other B-cell malignancies, both as monotherapy and in combinations. In this review, we discuss results from clinical trials evaluating the efficacy and safety of acalabrutinib in patients with CLL, MCL, and Waldenstrom\u2019s macroglobulinemia. Recent phase 3 data showed that acalabrutinib improved progression-free survival (PFS) compared with rituximab plus idelalisib or rituximab plus bendamustine in patients with relapsed\/refractory CLL, and acalabrutinib with or without obinutuzumab improved PFS compared with chlorambucil plus obinutuzumab in patients with treatment-na\u00efve CLL. Overall, acalabrutinib had a tolerable safety profile, with most adverse events being grade 1\/2 severity (most commonly headache and diarrhea) and a low rate of discontinuation due to adverse events.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2021.668162","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T10:41:12Z","timestamp":1620988872000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies"],"prefix":"10.3389","volume":"11","author":[{"given":"Hussein A.","family":"Abbas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"B1","unstructured":"Cancer Stat Facts: non-Hodgkin Lymphoma"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24086","article-title":"Non-Hodgkin Lymphoma Subtype Distribution, Geodemographic Patterns, and Survival in the US: A Longitudinal Analysis of the National Cancer Data Base From 1998 to 2011","volume":"90","author":"Al-Hamadani","year":"2015","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/361226a0","article-title":"The Gene Involved in X-linked Agammaglobulinaemia is a Member of the Src Family of Protein-Tyrosine Kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90667-f","article-title":"Deficient Expression of a B Cell Cytoplasmic Tyrosine Kinase in Human X-linked Agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.10.5715","article-title":"Cutting Edge: Constitutive B Cell Receptor Signaling is Critical for Basal Growth of B Lymphoma","volume":"176","author":"Gururajan","year":"2006","journal-title":"J Immunol"},{"key":"B6","unstructured":"US FDA Approves Astrazeneca\u2019s Calquence (Acalabrutinib) for Adult Patients With Previously-Treated Mantle Cell Lymphoma [Press Release]2017"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA Approval: Ibrutinib for Patients With Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B8","volume-title":"Imbruvica (Ibrutinib) [Prescribing Information]","author":"Janssen","year":"2020"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK With Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens Versus Chemoimmunotherapy in Older Patients With Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-Term Efficacy and Safety of First-Line Ibrutinib Treatment for Patients With CLL\/SLL: 5 Years of Follow-Up From the Phase 3 RESONATE-2 Study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001883","article-title":"Current Understanding of Bleeding With Ibrutinib Use: A Systematic Review and Meta-Analysis","volume":"1","author":"Caron","year":"2017","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-Associated Atrial Fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib Increases the Risk of Hypertension and Atrial Fibrillation: Systematic Review and Meta-Analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor With a Differentiated Selectivity and In Vivo Potency Profile","volume":"363","author":"Barf","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance Mechanisms for the Bruton\u2019s Tyrosine Kinase Inhibitor Ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"B19","volume-title":"Calquence (Acalabrutinib) [Prescribing Information]","year":"2019"},{"key":"B20","unstructured":"FDA Takes Second Action Under International Collaboration, Approves New Treatment Option for Patients With Chronic Lymphocytic Leukemia [FDA News Release]2019"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib With or Without Obinutuzumab Versus Chlorambucil and Obinutuzmab for Treatment-Naive Chronic Lymphocytic Leukaemia (ELEVATE TN): A Randomised, Controlled, Phase 3 Trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355","article-title":"Ascend: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in Relapsed or Refractory Mantle Cell Lymphoma (ACE-LY-004): A Single-Arm, Multicentre, Phase 2 Trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib Monotherapy in Patients With Waldenstrom Macroglobulinemia: A Single-Arm, Multicentre, Phase 2 Study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"Abstract 7501","DOI":"10.1200\/JCO.2018.36.15_suppl.7501","article-title":"Acalabrutinib in Patients (Pts) With Waldenstr\u00f6m Macroglobulinemia (WM) [Abstract]","volume":"36","author":"Owen","year":"2018","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638","article-title":"Final Analysis From RESONATE: Up to Six Years of Follow-Up on Ibrutinib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in Previously Treated Waldenstrom\u2019s Macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients With Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"Abstract 2597","DOI":"10.1158\/1538-7445.AM2015-2597","article-title":"Bgb-3111 is a Novel and Highly Selective Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor [Abstract]","volume":"75","author":"Li","year":"2015","journal-title":"Cancer Res"},{"key":"B32","unstructured":"FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma2019"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0163","article-title":"A Head-to-Head Phase III Study Comparing Zanubrutinib Versus Ibrutinib in Patients With Waldenstrom Macroglobulinemia","volume":"14","author":"Tam","year":"2018","journal-title":"Future Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1182\/blood-2019-125483","article-title":"Treatment With the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL): Updated Results From a Phase 1\/2 Trial [Abstract]","volume":"134","author":"Cull","year":"","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 Study of the Selective BTK Inhibitor Zanubrutinib in B-cell Malignancies and Safety and Efficacy Evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844","article-title":"A Randomized Phase 3 Trial of Zanubrutinib vs Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: The ASPEN Study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32010","article-title":"Selective BTK Inhibition Improves Bendamustine Therapy Response and Normalizes Immune Effector Functions in Chronic Lymphocytic Leukemia","volume":"144","author":"Lee-Verges","year":"2019","journal-title":"Int J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.140806","article-title":"Phase I Study of Single-Agent CC-292, a Highly Selective Bruton\u2019s Tyrosine Kinase Inhibitor, in Relapsed\/Refractory Chronic Lymphocytic Leukemia","volume":"101","author":"Brown","year":"2016","journal-title":"Haematologica"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-Year Follow-Up of Treatment-Naive and Previously Treated Patients With CLL and SLL Receiving Single-Agent Ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1182\/blood-2019-131025","article-title":"A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO\/GS-4059) and Idelalisib With and Without Obinutuzumab in Patients With Relapsed\/Refractory Chronic Lymphocytic Leukemia (CLL) [Abstract]","volume":"134","author":"Kutsch","year":"2019","journal-title":"Blood"},{"key":"B42","volume-title":"Brukinsa (Zanubrutinib) [Prescribing Information]","year":""},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.220590","article-title":"Differential Effects of BTK Inhibitors Ibrutinib and Zanubrutinib on NK-cell Effector Function in Patients With Mantle Cell Lymphoma","volume":"105","author":"Flinsenberg","year":"2020","journal-title":"Haematologica"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00235-X","article-title":"Pirtobrutinib Shows Evidence to Inaugurate a Third Generation of BTK Inhibitors","volume":"397","author":"Michot","year":"2021","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1182\/blood-2018-99-109973","article-title":"Potency and Selectivity of BTK Inhibitors in Clinical Development for B-cell Malignancies [Abstract]","volume":"132","author":"Kaptein","year":"2018","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017011999","article-title":"Severe Platelet Dysfunction in NHL Patients Receiving Ibrutinib is Absent in Patients Receiving Acalabrutinib","volume":"1","author":"Bye","year":"2017","journal-title":"Blood Adv"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.207183","article-title":"Differences and Similarities in the Effects of Ibrutinib and Acalabrutinib on Platelet Functions","volume":"104","author":"Series","year":"2019","journal-title":"Haematologica"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib Monotherapy in Patients With Relapsed\/Refractory Chronic Lymphocytic Leukemia: Updated Phase 2 Results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1182\/blood-2018-99-110451","article-title":"Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results From the Phase 1\/2 ACE-CL-001 Study [Abstract]","volume":"132","author":"Byrd","year":"2018","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"Abstract 8024","DOI":"10.1200\/JCO.2020.38.15_suppl.8024","article-title":"Acalabrutinib in Treatment-Na\u00efve Chronic Lymphocytic Leukemia: Mature Results From Phase II Study Demonstrating Durable Remissions and Long-Term Tolerability [Abstract]","volume":"38","author":"Byrd","year":"2020","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"Abstract 7500","DOI":"10.1200\/JCO.2019.37.15_suppl.7500","article-title":"Acalabrutinib With Obinutuzumab (Ob) in Treatment-Naive (TN) and Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL): Three-year Follow-Up [Abstract]","volume":"37","author":"Woyach","year":"2019","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib Monotherapy in Patients With Chronic Lymphocytic Leukemia Who are Intolerant to Ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"key":"B53","doi-asserted-by":"publisher","first-page":"Abstract 7530","DOI":"10.1200\/JCO.2019.37.15_suppl.7530","article-title":"Phase 2 Study of Acalabrutinib in Ibrutinib (IBR)-Intolerant Patients (Pts) With Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL) [Abstract]","volume":"37","author":"Rogers","year":"2019","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"Abstract 7518","DOI":"10.1200\/JCO.2018.36.15_suppl.7518","article-title":"Acalabrutinib Combined With PI3K\u03b4 Inhibitor ACP-319 in Patients (Pts) With Relapsed\/Refractory (R\/R) B-cell Malignancies [Abstract]","volume":"36","author":"Barr","year":"2018","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"Abstract 7519","DOI":"10.1200\/JCO.2019.37.15_suppl.7519","article-title":"Phase 1\/2 Trial of Acalabrutinib Plus Pembrolizumab (Pem) in Relapsed\/Refractory (R\/R) Diffuse Large B-cell Lymphoma (DLBCL) [Abstract]","volume":"37","author":"Witzig","year":"2019","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/blood.V130.Suppl_1.4326.4326","article-title":"Pooled Analysis of Safety Data From Clinical Trials Evaluating Acalabrutinib Monotherapy in Hematologic Malignancies [Abstract]","volume":"130","author":"Byrd","year":"2017","journal-title":"Blood"},{"key":"B57","article-title":"Management of Adherence and Adverse Events in Patients With Mantle Cell Lymphoma Treated With Acalabrutinib: The MD Anderson Cancer Center Experience","author":"Badillo","year":"2018"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-Associated Bleeding: Pathogenesis, Management and Risk Reduction Strategies","volume":"15","author":"Shatzel","year":"2017","journal-title":"J Thromb Haemost"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.09.012","article-title":"Matching-Adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed\/Refractory Mantle Cell Lymphoma","volume":"41","author":"Telford","year":"2019","journal-title":"Clin Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2019-127674","article-title":"Resistance to Acalabrutinib in CLL is Mediated Primarily by BTK Mutations [Abstract]","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1182\/blood-2018-99-110617","article-title":"Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients With Treatment-Naive (TN) or Relapsed\/Refractory (R\/R) Mantle Cell Lymphoma (MCL) [Abstract]","volume":"132","author":"Phillips","year":"2018","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1182\/blood.V130.Suppl_1.432.432","article-title":"Acalabrutinib With Obinutuzumab in Relapsed\/Refractory and Treatment-Naive Patients With Chronic Lymphocytic Leukemia: The Phase 1b\/2 ACE-CL-003 Study","volume":"130","author":"Woyach","year":"2017","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/blood.V130.Suppl_1.498.498","article-title":"Acalabrutinib Monotherapy in Patients With Relapsed\/Refractory Chronic Lymphocytic Leukemia: Updated Results From the Phase 1\/2 ACE-CL-001 Study","volume":"130","author":"Byrd","year":"2017","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) has Significant Activity in Patients With Relapsed\/Refractory B-cell Malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"B65","article-title":"First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia [Abstract]","author":"Byrd","year":"","journal-title":"Am Soc Clin Oncol Annu Meeting"},{"key":"B66","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-cell Malignancies and Overcoming Therapeutic Resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.1182\/blood-2019-123057","article-title":"A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination With Venetoclax With or Without Obinutuzumab, Compared With Investigator\u2019s Choice of Chemoimmunotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation [Abstract]","volume":"134","author":"Brown","year":"2019","journal-title":"Blood"},{"key":"B68","article-title":"Updated Safety and Efficacy Results From a Phase 2 Study of Acalabrutinib, Ventoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL) [Abstract]","author":"Davids","year":"2020"},{"key":"B69","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-136317","article-title":"Acalabrutinib in Combination With Venetoclax and Obinutuzumab or Rituximab in Patients With Treatment-Na\u00efve or Relapsed\/Refractory Chronic Lymphocytic Leukemia [Abstract]","author":"Woyach","year":"2020"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-841015","article-title":"B-Cell Receptor-Mediated NFATc1 Activation Induces IL-10\/STAT3\/PD-L1 Signaling in Diffuse Large B-cell Lymphoma","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0481-7","article-title":"Targeted Therapies in CLL: Monotherapy Versus Combination Approaches","volume":"13","author":"Khan","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"B72","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab in First-Line Treatment of Chronic Lymphocytic Leukaemia (iLLUMINATE): A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-184","article-title":"Murano Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL)","volume":"132","author":"Seymour","year":"2018","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia (CLL14): Follow-Up Results From a Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood-2019-127506","article-title":"Preliminary Safety and Efficacy Results From a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) [Abstract]","volume":"134","author":"Lampson","year":"2019","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1811271","article-title":"Comparison of Acalabrutinib Plus Obinutuzumab, Ibrutinib Plus Obinutuzumab and Venetoclax Plus Obinutuzumab for Untreated CLL: A Network Meta-Analysis","volume":"61","author":"Sheng","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B77","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1182\/blood-2019-130062","article-title":"Toxicities and Outcomes of Acalabrutinib-Treated Patients With Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients [Abstract]","volume":"134","author":"Yazdy","year":"2019","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.668162\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T10:41:21Z","timestamp":1620988881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.668162\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":77,"alternative-id":["10.3389\/fonc.2021.668162"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.668162","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]},"article-number":"668162"}}